%0 Journal Article
%T Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX
%A Akiko Todaka
%A Akira Fukutomi
%A Hideki Ueno
%A Hideyuki Hayashi
%A Hirofumi Fujii
%A Hiromichi Shirasu
%A Katsuhiro Omae
%A Kazuhiro Uesugi
%A Keiko Kamei
%A Kentaro Sudo
%A Marina Kobayashi
%A Masato Ozaka
%A Naohiro Okano
%A Nobumasa Mizuno
%A Noritoshi Kobayashi
%A Satoshi Kobayashi
%A Seigo Yukisawa
%A Yosuke Horita
%J Archive of "Cancer Science".
%D 2019
%R 10.1111/cas.13883
%X Studies have indicated an association between UDP©\glucuronosyltransferase©\1A1 (UGT1A1) genetic polymorphisms and irinotecan©\induced toxicity. We undertook this study to investigate the association between UGT1A1 genetic polymorphisms and toxicity in patients treated with the FOLFIRINOX (comprising oxaliplatin, irinotecan, fluorouracil, and leucovorin) chemotherapy regimen in the JASPAC 06 study. Patients screened for UGT1A1*6 and UGT1A1*28, and treated with either the original FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 200 mg/m2, bolus 5©\fluorouracil [5©\FU] 400 mg/m2, and continuous 5©\FU 2400 mg/m2) or a modified FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 200 mg/m2, and continuous 5©\FU 2400 mg/m2) as first©\line chemotherapy were included. Of 199 patients eligible for this analysis, 79 patients were treated with the original FOLFIRINOX regimen and 120 patients were treated with the modified FOLFIRINOX regimen. In the original FOLFIRINOX group, 54 were UGT1A1 WT, and 25 were UGT1A1 heterozygous type (£¿/*6, 12 patients; £¿/*28, 13 patients). In the modified FOLFIRINOX group, 64 were UGT1A1 WT and 56 were UGT1A1 heterozygous type (£¿/*6, 33 patients; £¿/*28, 23 patients)
%K chemotherapy
%K FOLFIRINOX
%K pancreatic cancer
%K toxicity
%K UGT1A1
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361560/